Hangzhou Sciwind Biosciences

NCT07836270

Phase 3, Not yet recruiting, 2026, 192 people, 23 Sept 2026, clinicaltrials.gov

NCT07734311

Phase 3, Recruiting, 2026, 360 people, 29 Jul 2026, clinicaltrials.gov

NCT07387094

Phase 3, Recruiting, 2026, 140 people, 4 Feb 2026, clinicaltrials.gov

NCT07243171

Phase 1/2, Recruiting, 2025, 126 people, 21 Nov 2025, clinicaltrials.gov

NCT07073417

Phase 2, Active, not recruiting, 2025, 163 people, 18 Jul 2025, clinicaltrials.gov

NCT06335134

Phase 1, Completed, 2023, 57 people, 28 Mar 2024, clinicaltrials.gov

NCT05680155

Phase 3, Completed, 2022, 211 people, 11 Jan 2023, clinicaltrials.gov

NCT05680129

Phase 3, Completed, 2023, 623 people, 11 Jan 2023, clinicaltrials.gov

NCT05184322

Collaborator, Phase 1, Completed, 2022, 87 people, 11 Jan 2022, clinicaltrials.gov

NCT05111912

Collaborator, Phase 2, Completed, 2021, 206 people, 8 Nov 2021, clinicaltrials.gov

Efficacy and Safety of cAMP-Biased Ecnoglutide vs. Unbiased Semaglutide in Adults with Obesity: Twenty-Week Results from a Multicenter, Randomized, Open-Label, Phase 2 Study

ADA Scientific Sessions 2026 abstract, 6 Jun 2026